Dyve Biosciences
Dyve Biosciences is a clinical-stage biotech company that leverages proprietary transdermal delivery technology to develop therapies targeting acidic microenvironments in diseases such as cancer and immunological conditions. Their innovative platform, DMAX, allows for the topical application and transdermal delivery of complex molecules, aiming to create patient-friendly and clinically intuitive therapeutics. Their lead asset, DYV702, has shown promising results in clinical trials for reducing pain in acute gouty arthritis and is exploring applications in oncology and immunology.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Topical pH-modulating therapeutic (clinical candidate for acute gout)
A topical buffering/alkalinizing formulation developed to reduce pain intensity and duration of acute gout flares by locally increasing extracellular pH at the affected joint; advanced in Phase 2 clinical studies.
Topical/systemic buffering candidate for oncology applications
A topical buffering formulation intended to increase extracellular pH in solid tumors to potentially reduce tumor aggressiveness and improve responses to anticancer therapies; supported by preclinical murine tumor model data and academic collaboration results.
Topical pH-modulating therapeutic (clinical candidate for acute gout)
A topical buffering/alkalinizing formulation developed to reduce pain intensity and duration of acute gout flares by locally increasing extracellular pH at the affected joint; advanced in Phase 2 clinical studies.
Topical/systemic buffering candidate for oncology applications
A topical buffering formulation intended to increase extracellular pH in solid tumors to potentially reduce tumor aggressiveness and improve responses to anticancer therapies; supported by preclinical murine tumor model data and academic collaboration results.
Services
Joint laboratory studies with academic cancer centers to evaluate transdermal buffering agents in tumor models and validate translational endpoints.
Design and conduct of multi-center Phase 2 clinical studies including protocol development, site coordination, data collection, and safety monitoring.
Formulation development and translational testing to enable topical delivery of molecules with poor oral/injectable suitability and to optimize onset and pharmacokinetics.
Joint laboratory studies with academic cancer centers to evaluate transdermal buffering agents in tumor models and validate translational endpoints.
Design and conduct of multi-center Phase 2 clinical studies including protocol development, site coordination, data collection, and safety monitoring.
Formulation development and translational testing to enable topical delivery of molecules with poor oral/injectable suitability and to optimize onset and pharmacokinetics.
Expertise Areas
- Transdermal drug delivery
- pH modulation of disease microenvironments (TME and inflamed tissue)
- Formulation and emulsion chemistry for topical/systemic delivery
- Clinical trial design and multi-center execution (randomized, double-blind, placebo-controlled Phase 2)
Key Technologies
- Emulsion-based transdermal delivery
- Skin lipid matrix fluidization and tight junction modulation
- Transdermal delivery of buffering/alkalinizing agents
- Topical formulation development for rapid onset systemic exposure
News & Updates
Preclinical data showcasing the delivery approach that unlocks the effects of neutralizing tumor microenvironment acidity.
Results from a Phase 2 study showing significant reduction in pain and faster resolution in gout patients.
Tatyana Beldock joins the board bringing extensive experience in healthcare and biotech.
The presentation demonstrated the ability of transdermal delivery to modulate tumor microenvironment pH, potentially impacting tumor progression.
Successful Phase 2 Clinical Study of DYV702 for Gout Pain
Completed a multi-center, 100-patient, Phase 2 clinical trial showing significant pain reduction and faster resolution.
FDA Clearance for Phase 2 Study of DYV700 for Gout Pain
Received FDA approval to proceed with a Phase 2 trial evaluating topical DYV700 for acute gout flare.
Preclinical data showcasing the delivery approach that unlocks the effects of neutralizing tumor microenvironment acidity.
Results from a Phase 2 study showing significant reduction in pain and faster resolution in gout patients.
Tatyana Beldock joins the board bringing extensive experience in healthcare and biotech.
The presentation demonstrated the ability of transdermal delivery to modulate tumor microenvironment pH, potentially impacting tumor progression.
Successful Phase 2 Clinical Study of DYV702 for Gout Pain
Completed a multi-center, 100-patient, Phase 2 clinical trial showing significant pain reduction and faster resolution.
FDA Clearance for Phase 2 Study of DYV700 for Gout Pain
Received FDA approval to proceed with a Phase 2 trial evaluating topical DYV700 for acute gout flare.